Login to Your Account

Clinic Roundup

Thursday, November 29, 2012

• Nymox Pharmaceutical Corp., of Hasbrouck Heights, N.J., said it completed patient enrollment in its pivotal Phase III NX02-0017 study testing NX-1207 in benign prostatic hyperplasia. Top-line results are expected in late 2013.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription